Last reviewed · How we verify
NCT05624606
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
Phase 1, PHASE2 trial testing Quadrivalent Influenza mRNA Vaccine MRT5410 in Influenza Immunization in 682 participants. Completed in 28 March 2024.
28 March 2024
Quick facts
| Lead sponsor | Sanofi Pasteur, a Sanofi Company |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 682 |
| Start date | 28 November 2022 |
| Primary completion | 28 March 2024 |
| Estimated completion | 28 March 2024 |
| Sites | 25 locations across Puerto Rico, United States |
Drugs / interventions tested
- Quadrivalent Influenza mRNA Vaccine MRT5410 — full drug profile →
- Quadrivalent Recombinant Influenza vaccine RIV4
- Quadrivalent Inactivated Influenza Standard Dose QIV-SD — full drug profile →
- Quadrivalent Inactivated Influenza High Dose QIV-HD — full drug profile →
Conditions studied
- Influenza Immunization — all drugs for Influenza Immunization →
Sponsor
Sanofi Pasteur, a Sanofi Company — full company profile →
Who can join
18 and older, any sex, with Influenza Immunization. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD \[adults ≥ 65 years of age only\], or RIV4) in adults 18 years of age and older.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05624606
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Influenza Immunization
Currently open trials in the same condition.
- NCT06727058 — Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older · Phase 1, PHASE2 · active not recruiting
- NCT06695117 — Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombin · Phase 1, PHASE2 · active not recruiting
- NCT06695130 — Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombin · Phase 1, PHASE2 · active not recruiting
Other Sanofi Pasteur, a Sanofi Company trials
Trials by the same sponsor.
- NCT07536048 — A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · not yet recruiting
- NCT07222059 — Phase 3 Single Arm, Open Study on vYF in Adults · Phase 3 · completed
- NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
- NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
- NCT06793826 — Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05624606 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company
- Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05624606.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing